Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries.

2025年1月31日 · Our goal is to revolutionize drug discovery and develop targeted medicines for some of the most challenging neurological conditions, primarily Alzheimer’s disease. We won’t stop pursuing breakthroughs until the world is cancer-free. That’s why we let the science drive us to new approaches that accelerate progress.

Eisai Co., Ltd. (Japanese: エーザイ株式会社, Hepburn: Ēzai Kabushiki-gaisha) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices. [3]

Myōan Eisai/Yōsai (明菴栄西, 27 May 1141 – 1 August 1215) was a Japanese Buddhist priest, credited with founding the Rinzai school, the Japanese line of the Linji school of Zen Buddhism. [1] In 1191, he introduced this Zen approach to Japan, following his trip to China from 1187 to 1191, during which he was initiated into the Linji ...

2024年3月31日 · About Eisai. Message from Top Management; Corporate Mission; Corporate Information; Corporate Governance; Business Activities; Video Library; Eisai at a Glance

Established in 1941, Eisai is a pharmaceutical company operating globally in terms of R&D, manufacturing and marketing, with a strong focus on prescription medicines. Under “EWAY Future & Beyond,” the 5 years from FY2021 are “EWAY Future,” while the term from FY2026 is “EWAY Beyond.”

Eisai came to America in 1987 with one goal in mind: Create innovative new medicines to help patients, their families and caregivers. We’ve been breaking through ever since, with solutions and therapies that help improve the lives of the people we serve.

Our U.S. Corporate Headquarters in Nutley, NJ, is the nerve center of a fully integrated pharmaceutical business focused on neurology and oncology. Here, we identify major medical challenges that Eisai is uniquely capable of tackling, set …

4 天之前 · NUTLEY, N.J., March 25, 2025 /PRNewswire/ -- Eisai Inc. announced today that the company will present the latest findings from its robust neurology portfolio, including data on real-world experience and continued maintenance dosing with our dual-acting, anti-amyloid beta (Aβ) protofibril* antibody for the treatment of Alzheimer's disease (AD), lecanemab (generic name, U.S. brand name: LEQEMBI ...

2022年11月21日 · eisai to present lecanemab real-world experience data and findings from neurology portfolio at the american academy of neurology (aan) annual meeting Feb 28, 2025 The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease